The incidence of CRS with CD19 combined with CD22 CAR T-cell therapy (58.2%, 95% CI: 37.8–77.3) was higher than that with CD19 combined with CD20 CAR T-cell therapy (54.5%, 95% CI: 36.3–72.2, Figure 8B), although the difference was not significant. Here, CD22 is linked to congenital rubella syndrome.